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Background: This Phase IV, open-label, multicentre, randomized study (MEnTOR) compared two low-dose recombinant
human follicle-stimulating hormone (r-hFSH) protocols for ovulation induction.
Methods: This study was conducted in six Middle Eastern countries between March 2009 and March 2011. Eligible
women (18–37 years), with World Health Organization Group II anovulatory infertility, were randomized to receive r-hFSH
(starting daily dose: 75 IU) as a chronic low-dose (CLD) (37.5 IU dose increase on Day 14) or low-dose (LD) (37.5 IU dose
increase on Day 7) protocol if no follicles were ≥10 mm. The maximum r-hFSH daily dose permitted was 225 IU/day. The
total length of ovarian stimulation could not exceed 35 days, unless ultrasound assessment suggested imminent follicular
growth and maturation. Patients underwent only one treatment cycle. Primary endpoint: incidence of mono-follicular
development. Secondary endpoints included: stimulation duration and rates of bi-follicular development; human
chorionic gonadotrophin administration rate; clinical pregnancy; and cycle cancellation (owing to inadequate response).
Adverse events (AEs) were recorded. The primary efficacy analysis was performed using data from all patients who received
at least one dose of correct study medication, had at least one efficacy assessment, and no protocol violations at treatment
start (CLD group, n= 122; LD group, n= 125).
Results: Mono-follicular development rates (primary endpoint) were similar in both groups (CLD: 56.6% [69/122] versus LD:
55.2% [69/125], p = 0.93; primary efficacy analysis population). Similarly, there were no significant differences between
groups in bi-follicular development, clinical pregnancy or cycle cancellation (inadequate response) rates. In patients
who received human chorionic gonadotrophin injections, the mean duration of stimulation was 13.7 days in the
CLD group and 12.9 days in the LD group. Clinical pregnancy rates for those patients who received an hCG injection
were similar in both groups (CLD: 20.2% [19/94] versus LD: 19.8% [18/91], p = 0.94; primary efficacy analysis population).
Most AEs were mild in severity. Only one case of ovarian hyperstimulation syndrome was reported (mild; CLD group).
Conclusions: Efficacy and safety outcomes were similar for the two protocols.
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Ovulatory disorders account for approximately 30% of all
cases of infertility [1]. World Health Organization (WHO)
Group II anovulatory infertility is the most common form
of ovulatory dysfunction and is characterized by asynchron-
ous gonadotrophin production with follicle-stimulating
hormone (FSH) and oestradiol (E2) levels within the
normal range. A large proportion of women with WHO
Group II anovulatory infertility have polycystic ovary syn-
drome [2].
First-line therapy for WHO Group II anovulatory in-
fertility is usually clomiphene citrate (CC) [3,4]. How-
ever, a substantial proportion (approximately 40%) of
women with WHO Group II anovulatory infertility fail
to conceive following CC therapy [5]. Such patients may
benefit from gonadotrophin therapy to stimulate follicle
development and induce ovulation [1,4,6-9]. Ovulation
induction (OI), however, may be associated with the
serious complications of ovarian hyperstimulation syn-
drome (OHSS) and multiple pregnancy [9-11].
The amount of exogenous FSH required to induce fol-
licular development (the so-called FSH threshold) is
highly variable among individuals [12-16]. This is par-
ticularly important for women with WHO Group II an-
ovulatory infertility and polycystic ovarian morphology [5],
as the ovaries are extremely sensitive to gonadotrophin
stimulation [8].
Chronic low-dose (CLD) step-up FSH protocols have
been developed so that the lowest effective dose of FSH
can be used to achieve the objective of mono-follicular
development [5,16,17]. The classic CLD regimen involves
a low daily starting dose (usually 75 IU) for 14 days and, if
necessary, the FSH dose is increased in small increments
(37.5 IU), at intervals of no fewer than 7 days, until follicu-
lar development is initiated [8]. Combined data from 11
studies indicate that such CLD protocols result in a high
mono-ovulation rate (69% of cycles) and low multiple
pregnancy and OHSS rates (5.7% and 0.14% of cycles, re-
spectively) [8].
A modified protocol has also been developed and utilized
by some clinicians in an attempt to shorten treatment
schedules and reduce costs. In this so-called low-dose (LD)
protocol, the starting dose of FSH (75 IU) is maintained
for only 7 days before small incremental dose increases are
permitted [8]. However, evaluation of such LD protocols
comprises only one small single-centre study (n = 50),
which found that although the duration of FSH stimu-
lation was shorter, the risk of multi-follicular develop-
ment was greater than with CLD protocols [8].
Technological advances allow recombinant human (r-h)
FSH (follitropin alfa; GONAL-f®; Merck Serono S.A.–
Switzerland, a subsidiary of Merck KGaA, Darmstadt,
Germany) to be filled by mass (FbM) rather than by con-
ventional bioassay [18]. This results in high batch-to-batchconsistency and allows precise dosing of r-hFSH (follitro-
pin alfa), which is likely to be particularly beneficial when
using OI protocols with small dose increments. Indeed, it
is possible that the use of r-hFSH (follitropin alfa) FbM
may reduce the individual variability in ovarian response
[19]. In turn, this may result in measurable differences in
outcomes between LD and CLD protocols.
This article reports the findings of the first randomized,
multicentre study to compare the efficacy and safety of
CLD versus LD protocols for OI using r-hFSH (follitropin
alfa FbM). The primary objective of this post-marketing
study was to investigate the optimization of r-hFSH treat-
ment in patients with chronic anovulation.
Methods
Study design
This randomized, multicentre, open-label, Phase IV study
(Middle East Trial for Ovulation induction Responders
[MEnTOR]; NCT01081626) was conducted between
March 2009 and March 2011 in six Middle Eastern
countries (Egypt, Iran, Kuwait, Lebanon, Saudi Arabia
and United Arab Emirates). Ten sites were originally
involved, with three additional sites later added be-
cause of slow recruitment.
The study was performed in accordance with the
Declaration of Helsinki, the International Conference
on Harmonisation Harmonised Tripartite Guideline for
Good Clinical Practice and all applicable regulatory re-
quirements - see Additional file 1. Independent ethics
committee approval was obtained at each study centre.
Written informed consent was obtained from all patients
prior to study start.
Study population
Women aged 18–37 years with WHO Group II an-
ovulatory infertility (defined as a menstrual cycle dur-
ation >35 days or regular cycles with luteal-phase
progesterone [P4] levels <10 nmol/mL) and who wished
to conceive were eligible for inclusion in the study. Other
key inclusion criteria were: body mass index (BMI) >20
to ≤32 kg/m2; spontaneous or CC-induced menses, or a
positive progestin-induced withdrawal bleed within the
previous year; normal uterine cavity and ≥1 patent fallo-
pian tube; early follicular-phase FSH and prolactin levels
within the normal range; total antral follicle count ≥10
(follicles of ≥2 to <11 mm in diameter in both ovaries);
and a male partner with sperm considered normal based
on local standards.
Patients who had received CC or gonadotrophins within
1 month of screening were excluded from participation.
Other key exclusion criteria were: ovarian enlargement or
ovarian cyst (unrelated to polycystic ovary syndrome);
uterine fibroids; gynaecological bleeding of unknown aeti-
ology; history of ≥3 miscarriages, extra-uterine pregnancy
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Obstetricians and Gynaecologists criteria) [20]; clinically
relevant systemic condition (e.g. insulin-dependent dia-
betes); and medical conditions that in the investigator’s
opinion could prevent an effective response to treatment
(e.g. primary ovarian failure, malformations of the repro-
ductive organs incompatible with pregnancy) or affect the
absorption, distribution, metabolism or excretion of the
study drug.
Treatments and interventions
The study comprised a screening visit (between Days 7
and 28 of the cycle, before the patient was assigned to
treatment) followed by pre-stimulation, stimulation and
post-stimulation periods. Patients underwent only one
treatment cycle.
FSH, E2, luteinizing hormone and prolactin levels and
antral follicle count (determined by transvaginal ultra-
sound [TVUS]) were measured at the screening visit.
Following a negative pregnancy test, patients were ran-
domized (1:1) to receive daily r-hFSH (follitropin alfa
FbM) administered subcutaneously according to either a
CLD or an LD protocol. Treatment allocation was deter-
mined by a computer-generated randomization list andFigure 1 Treatment protocols. aWhen the leading follicle reached ≥17 m
of hCG was injected to trigger ovulation. bDuration of ovarian stimulation c
imminent follicular growth and maturation. The maximum permitted daily
every 7 days until a follicle of ≥10 mm was observed, and then scheduled
international units; r-hFSH = recombinant human follicle-stimulating hormobalanced in a 1:1 ratio within each site. Investigators re-
ceived randomization codes in individual sealed and num-
bered envelopes. At randomization, the investigator opened
the envelope with the next available number to reveal the
allocated treatment protocol, which was disclosed to both
patients and investigators. Following randomization, study
visits occurred weekly up to Day 35 (end of stimulation).
r-hFSH (follitropin alfa) was supplied in a pre-filled pen
for injection (the GONAL-f® Revised Formulation Female
pen; EMD Serono, Inc., Rockland, MA, USA [a subsidiary
of Merck KGaA, Darmstadt, Germany]) in three dose pre-
sentations (300, 450 or 900 IU). Administration of r-hFSH
was initiated by physicians but (depending on the study
centre) subsequent doses could be self-injected by patients;
details of self-administered injections were recorded by the
patient on a diary card.
In the CLD protocol, r-hFSH was initiated at a daily
dose of 75 IU with an increase of 37.5 IU on Day 14 if
no follicles ≥10 mm were observed. In the LD protocol,
r-hFSH was initiated at a daily dose of 75 IU with an in-
crease of 37.5 IU on Day 7 if no follicles ≥10 mm were
observed (Figure 1). In both protocols, subsequent dose
increases were possible using 37.5 IU increments at 7-day
intervals depending on ovarian response. The maximumm and no more than two follicles had reached >14 mm, a single dose
ould not exceed 35 days, unless ultrasound assessment suggested
dose of r-hFSH was 225 IU. Ovarian response was monitored by TVUS
according to local practice. hCG = human chorionic gonadotrophin; IU,
ne; TVUS, trans-vaginal ultrasound.
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ation of ovarian stimulation could not exceed 35 days, un-
less ultrasound assessment suggested imminent follicular
growth and maturation.
The ovarian response was monitored closely by TVUS
every 7 days until a follicle of at least 10 mm in diameter
was observed, and thereafter according to local practice.
When at least one follicle reached 10–12 mm in diam-
eter, the r-hFSH dose was maintained until the leading
follicle reached ≥17 mm and no more than two follicles
had reached >14 mm. A single dose of human chorionic
gonadotrophin (hCG) was then injected to trigger ovula-
tion. Either r-hCG 250 μg (Ovidrel®; EMD Serono, Inc.) ad-
ministered subcutaneously or urine-derived hCG 5000 IU
administered intramuscularly could be used. Intercourse
was recommended on the day of, and the day after, hCG
administration; intrauterine insemination could be per-
formed using cryopreserved semen if the partner was un-
available. Patients considered to have an under-response
(failure of at least one follicle to reach 10–12 mm in
diameter) or an over-response (more than three folli-
cles of >14 mm in diameter and/or E2 levels >900 pg/mL)
after 35 days of r-hFSH stimulation were withdrawn from
the study.
Serum P4 levels were measured 5–7 days and/or 8–10
days after hCG administration. Ovulation was assumed
if mid-luteal P4 levels were ≥9.4 ng/mL (30 nmol/L)
and/or pregnancy was achieved. A serum beta hCG preg-
nancy test was performed 15–20 days after hCG adminis-
tration (if menstruation did not occur). Clinical pregnancy
was confirmed by the presence of at least one foetal sac
on TVUS 35–42 days after hCG administration.
Outcomes
Efficacy outcomes
The primary efficacy endpoint was the incidence of mono-
follicular development, defined as the development of only
one follicle ≥17 mm in diameter (and ≤2 other intermedi-
ate [>14 mm] follicles) on or before Day 35 of stimulation.
Secondary endpoints were the incidence of bi-follicular
development (defined as the proportion of patients devel-
oping two follicles ≥17 mm in diameter and ≤1 other
intermediate [>14 mm] follicle); incidence of multi-
follicular development (more than three follicles >14 mm
in diameter); hCG administration rate; clinical pregnancy
rate; rate of cycle cancellation (defined as the proportion
of patients with cycle cancellation owing to an inadequate
response to stimulation [i.e. failure of at least one follicle
to reach ≥17 mm in diameter]); duration of r-hFSH stimu-
lation before hCG administration; and total r-hFSH dose
required.
The incidence of bi-follicular development was added
after the protocol was finalized to better evaluate the
two treatment protocols.Safety outcomes
Safety endpoints included the incidence and severity of
adverse events (AEs; including OHSS) and local toler-
ability of r-hFSH administration. AEs were recorded
until at least 15–20 days after hCG administration (or
20–30 days after the last dose of r-hFSH if the patient
was withdrawn prior to hCG administration). AEs that
occurred >30 days after the last dose of r-hFSH were
not recorded. The severity of AEs and their relation-
ship to the study drug was determined by the investi-
gator. Serious AEs and medically relevant ongoing/
unknown-outcome AEs were followed-up until reso-
lution or stabilization.
Multiple pregancy (confirmed by the presence of more
than one foetal sac on TVUS 35–42 days after hCG ad-
ministration) was also recorded as a safety endpoint.
Rates of multiple pregancy and miscarriage are only pre-
sented for patients who received hCG injections.
Statistical methods
The null hypothesis was that there was no difference in the
proportion of patients achieving mono-follicular growth in
each treatment group.
Determination of the target sample size was based on
a single analysis of the primary endpoint using the
Chi-square test and applying a two-sided 5% alpha level
of significance. A mono-follicular development rate of
69% was reported in a previous study using a step-up
urine-derived hFSH protocol with a starting dose of
75 IU [8]. A sample size of 134 evaluable patients per
treatment group would be required to achieve 80% power
to detect a 15% difference in the rate of mono-follicular
development between groups, assuming a true rate of 70%
in the LD protocol group. Enrolment of 150 women per
treatment group was planned to allow for withdrawals
and non-evaluable data.
The primary efficacy analysis was performed using
data from all patients who received at least one dose of
the correct study medication, had at least one efficacy
assessment, and no protocol violations at the start of
treatment. Secondary supportive analyses were per-
formed using the per-protocol (PP) population (pa-
tients from the primary efficacy analysis population
who received all doses of study medication, excluding
patients with protocol deviations during the course of
treatment). The safety population included all patients
who received at least one dose of study medication and
had one follow-up visit.
The primary and secondary efficacy endpoints were
analysed using the Chi-square test, with the difference
between treatment groups analysed using a 95% confi-
dence interval, and a p-value was provided. Analysis of
variance was used to evaluate the duration of stimulation
and the dose of r-hFSH required.
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Patient population
Of the 320 patients who were screened, 310 were ran-
domized and received at least one dose of study treat-
ment: 155 patients in each treatment group (Figure 2).
Thirteen patients were withdrawn prematurely from the
study due to pregnancy before stimulation (n = 2), finan-
cial reason (n = 1), patient decision (n = 1) or lost to
follow up (n = 9). A further 50 patients were excluded
from evaluations: 45 due to protocol violations (age-
related [n = 9], BMI-related [n = 30], high FSH [n = 1],
high prolactin [n = 5]) and 5 who were randomized toFigure 2 Patient disposition. Patients were considered to have had an u
10–12 mm in diameter after 35 days of r-hFSH stimulation. Patients were c
three follicles of >14 mm in diameter and/or their E2 levels were >900 pg/
BMI = body mass index; CLD = chronic low-dose; E2 = oestradiol; hCG = hum
PRL = prolactin; r-hFSH = recombinant human follicle-stimulating hormonethe wrong treatment. The primary efficacy analysis popu-
lation comprised 247 patients: 122 patients in the CLD
group and 125 in the LD group. Patients’ demographic
and baseline characteristics were similar in the two groups
(primary efficacy analysis population; Table 1).
A total of 189 patients were included in the PP popu-
lation (95 and 94 patients in the CLD and LD groups,
respectively; Figure 2).
Efficacy
Similar rates of mono-follicular development (primary
endpoint) were achieved in the CLD and LD groups innder-response if there was failure to develop at least one follicle of
onsidered to have had an over-response if they developed more than
mL after 35 days of r-hFSH stimulation. AFC = antral follicle count;
an chorionic gonadotrophin; LD = low-dose; PP = per-protocol;
.
Table 1 Patients’ demographic and baseline fertility
characteristics overall and by treatment group (primary
efficacy analysis population)
Variable CLD group LD group Total
(n = 122) (n = 125) (N = 247)
Age, yearsa n 122 124 246
Mean (SD) 27.5 (4.42) 27.9 (4.33) 27.7 (4.37)
BMI, kg/m2 a n 119 124 243
Mean (SD) 26.4 (2.95) 26.0 (3.14) 26.2 (3.05)
Raceb n 122 124 246
Arab n (%) 68 (55.7) 69 (55.6) 137 (55.7)
Asian n (%) 19 (15.6) 16 (12.9) 35 (14.2)
Black n (%) 1 (0.8) 4 (3.2) 5 (2.0)
Caucasian n (%) 33 (27.1) 34 (27.4) 67 (27.2)
Other n (%) 1 (0.8) 1 (0.8) 2 (0.8)
Infertility typeb n 122 125 247
Primary n (%) 92 (75.4) 96 (76.8) 188 (76.1)
Secondary n (%) 30 (24.6) 29 (23.2) 59 (23.9)
Duration of
infertility, yearsa
n 122 125 247
Mean (SD) 3.8 (2.57) 4.2 (2.48) 4.0 (2.53)
Cause of infertilityb n 123c 127c 250c
Ovulatory
dysfunction
n (%) 120 (97.6) 121 (95.3) 241 (96.4)
Tubal factor n (%) 0 (0.0) 1 (0.8) 1 (0.4)
Other n (%) 3 (2.4) 5 (3.9) 8 (3.2)
Previous infertility
treatmentb
n 122 125 247
Yes n (%) 90 (73.8) 103 (82.4) 193 (78.1)
No n (%) 32 (26.2) 22 (17.6) 54 (21.9)
Previous pregnanciesb n 122 125 247
None n (%) 92 (75.4) 94 (75.2) 186 (75.3)
At least one n (%) 30 (24.6) 31 (24.8) 61 (24.7)
aNot significant; t-test.
bNot significant; Chi-square test.
cMultiple causes of infertility in three patients (CLD group, n = 1;
LD group, n = 2).
BMI = body mass index; CLD = chronic low-dose; LD = low-dose;
SD = standard deviation.
Table 2 Primary and secondary efficacy endpoint results
in the primary efficacy analysis population
Efficacy endpoint CLD group LD group p
(n = 122) (n = 125)
Mono-follicular developmenta 69 (56.6) 69 (55.2) 0.93
Bi-follicular developmenta 17 (13.9) 22 (17.6) 0.54
Multi-follicular developmenta 17 (13.9) 15 (12.0) 0.79
Cycle cancellation rateb 19 (15.6) 19 (15.2) 0.94
hCG injection rate 94 (77.1) 91 (72.8) 0.53
Clinical pregnancy ratec 19 (20.2) 18 (19.8) 0.94
Data are n (%).
aNumber of patients with follicles ≥17 mm in diameter by Day 35
of stimulation.
bDue to inadequate response.
cPregnancy rate calculated per patients who received hCG injections
(CLD group, n = 94; LD group, n = 91).
p values show the difference between treatment groups, using the
Chi-square test.
CLD = chronic low-dose; hCG = human chorionic gonadotrophin;
LD = low-dose.
Table 3 Primary and secondary efficacy endpoint results
in the per-protocol population
Efficacy endpoint CLD group LD group
p
(n = 95) (n = 94)
Mono-follicular developmenta 61 (64.2) 59 (62.8) 0.96
Bi-follicular developmenta 16 (16.8) 19 (20.2) 0.68
Multi-follicular developmenta 11 (11.6) 10 (10.6) 0.84
Cycle cancellation rateb 7 (7.4) 6 (6.4) 0.79
hCG injection rate 84 (88.4) 82 (87.2) 0.98
Clinical pregnancy ratec 17 (20.2) 17 (20.7) 0.37
Data are n (%).
aNumber of patients with follicles ≥17 mm in diameter by Day 35
of stimulation.
bDue to inadequate response.
cPregnancy rate calculated per patients who received hCG injections (CLD
group, n = 84; LD group, n = 82).
p values show the difference between treatment groups, using the
Chi-square test.
CLD = chronic low-dose; hCG = human chorionic gonadotrophin;
LD = low-dose.
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and 55.2% (69/125), respectively (p = 0.93; Table 2). This
was also the case in the PP population: 64.2% (61/95)
and 62.8% (59/94), respectively (p = 0.96; Table 3).
No significant differences between treatment groups
were found in the secondary efficacy endpoints. Rates of
bi-follicular development, multi-follicular development,
and hCG administration in the primary efficacy and PP
populations are presented in Table 2 and 3. Clinical preg-
nancy rates for those patients who received an hCG injec-
tion were 20.2% (19/94) and 19.8% (18/91) in the CLD
and LD groups, respectively (p = 0.94; primary efficacyanalysis population; Table 2). The rate of cycle cancellation
owing to inadequate response was 15.6% (19/122) of patients
in the CLD group and 15.2% (19/125) of patients in the LD
group (p = 0.94, primary efficacy analysis population).
In those patients who received an hCG injection, the
mean duration of r-hFSH stimulation required for OI,
while not statistically significant, was slightly longer in
the CLD than in the LD group (13.7 versus 12.9 days, re-
spectively; primary efficacy analysis population; Table 4).
In addition, the mean daily and total doses of r-hFSH re-
quired were slightly lower in the CLD group versus the LD
group, although only mean daily dose showed a statistically
significant difference between groups (Table 4 and 5).
Table 4 Duration of recombinant human follicle-stimulating hormone (r-hFSH) stimulation and total and daily r-hFSH
doses required - primary efficacy analysis population (patients who received hCG injections)
CLD group LD group Total
p
(n = 94) (n = 91) (N = 185)
Duration of stimulation, days 13.7 +/− 6.33 12.9 +/− 5.58 13.3 +/− 5.97 0.36
Daily dose, IU 78.7 +/− 8.90 85.0 +/− 15.35 81.8 +/− 12.86 <0.001
Total dose, IU 1119.4 +/− 690.04 1155.5 +/− 730.45 1137.2 +/− 708.50 0.73
Data are mean +/− standard deviation.
p values show the difference between treatment groups using analysis of variance.
Values in bold are significant.
CLD = chronic low-dose; hCG = human chorionic gonadotrophin; LD = low-dose.
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Of the 135 patients included in the safety population, 30/70
(43%) in the CLD group and 31/65 (48%) in the LD group
experienced at least one AE, excluding injection-site reac-
tions. In total, 121 AEs were reported (53 in the CLD
group; 68 in the LD group). The majority of AEs were mild
in severity (106/121; 87.6%), with only 11 (9.1%) moderate
and two (1.7%) severe AEs reported (the severity of two
AEs was not recorded). There was only one report of
OHSS (CLD group), which was mild in severity and re-
solved without sequelae. However, the patient was with-
drawn from the study as discontinuation was mandatory
following the development of OHSS.
Only one AE resulted in treatment discontinuation
and two resulted in modification of treatment. One ser-
ious AE was reported: an ectopic pregnancy (moderate
in severity) occurred in a patient in the LD group and
was considered to be unrelated to the study drug. The
patient was hospitalized and successfully managed with
medical treatment (methotrexate). The ectopic pregnancy
resolved without sequelae.
No significant difference was found between multiple
pregnancy rates in the CLD and LD groups for patients
who received hCG: 3.2% (3/94) versus 1.1% (1/91), re-
spectively (p = 0.34), in the primary efficacy analysis
population and 2.4% (2/84) versus 1.2% (1/82), respect-
ively (p = 0.58), in the PP population. All multiple preg-
nancies reported were twins. No significant difference
was found between miscarriage rates (for patients who
received hCG) in the CLD and LD groups: 4.3% (4/94)Table 5 Duration of recombinant human follicle-stimulating h
doses required - Per-protocol population (patients who receiv
CLD group
(n = 84)
Duration of stimulation, days 13.4 +/− 6.04
Daily dose, IU 78.5 +/− 8.95
Total dose, IU 1092.9 +/− 665.19 1
Data are mean +/− standard deviation.
p values show the difference between treatment groups using analysis of variance.
Values in bold are significant.
CLD = chronic low-dose; hCG = human chorionic gonadotrophin; LD = low-dose.versus 6.6% (6/91), respectively (p = 0.48), for the primary
efficacy analysis population and 4.8% (4/84) versus 6.1%
(5/82), respectively (p = 0.70), for the PP population.
Injection-site tolerability
Treatment diaries were provided by 150 patients (CLD
group: n = 73; LD group: n = 77). Of these, 42 patients
(28%) reported ≥1 r-hFSH injection-site reaction (CLD
group: n = 19; 26.0%; LD group: n = 23; 29.9%). The r-hFSH
injection-site reactions reported were pain (CLD group:
n = 9; LD group: n = 20), redness (CLD group: n = 2;
LD group: n = 5), bruising (CLD group: n = 6; LD group:
n = 2), swelling (CLD group: n = 4; LD group: n = 1) and
irritation (CLD group: n = 2; LD group: n = 3).
Discussion
To the authors’ knowledge, the MEnTOR study is the
first large, randomized, multicentre trial to compare the
efficacy and safety of a CLD versus LD step-up OI treat-
ment protocol using follitropin alfa FbM (r-hFSH). Pre-
viously reported data from a small, single-centre study
suggested that the LD protocol may substantially reduce
the FSH dose requirement and mean treatment duration
versus the CLD protocol while maintaining similar preg-
nancy rates [8]. However, the LD protocol may be asso-
ciated with a higher multiple pregnancy rate than the
CLD protocol [8]. The high batch-to-batch consistency
and precise dosing of follitropin alfa FbM was expected
to allow any differences in outcomes of the two treat-




(n = 82) (N = 166)
13.0 +/− 5.81 13.2 +/− 5.91 0.66
85.5 +/− 15.88 81.9 +/− 13.28 <0.001
183.1 +/− 762.52 1137.4 +/− 714.18 0.42
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alfa FbM has been reported to reduce the rate of OI
cycle cancellation owing to poor response (p < 0.02) and
increase the proportion of cycles not requiring a dose in-
crease (p < 0.001), compared with the follitropin alfa filled-
by-bioassay formulation [21]. Indeed, it is possible that the
reduced requirement for adjustment of the starting dose
when using follitropin alfa FbM [21] could explain the
similarity in outcomes of the CLD and LD protocols dem-
onstrated in the current study.
In the current study, the CLD and LD protocols demon-
strated similar efficacy, with no differences found in the
primary and secondary efficacy outcomes. In addition, the
two protocols were similar in terms of safety outcomes.
Of particular importance, similar rates of multiple preg-
nancy (among patients who received hCG) were reported
with the CLD and LD protocols (3.2% versus 1.1%, re-
spectively). It should be noted that the LD protocol was
associated with a slightly higher mean daily and total
r-hFSH dose requirement, but a shorter duration of
stimulation versus the CLD protocol.
Rates of clinical (20.2%) and multiple pregnancy (3.2%)
for patients who received hCG in the CLD group are in
line with a previous compilation of data from 11 CLD
protocol studies (21–45% and 0–14%, respectively) [8].
Mono-follicular and bi-follicular development rates re-
ported here in the CLD group are also similar to those
reported in two recent publications of similar CLD pro-
tocols (54–55% and 17–25%, respectively) [9,16]. Min-
imal data on the outcomes of LD treatment protocols
are available. The multiple pregnancy rate of the LD
protocol in the current study was lower than that re-
ported previously [8]; however, direct comparison of
data between studies is limited because of differences in
the methodology used to calculate rates.
The strengths of the current study include the large ran-
domized population (N = 310) recruited from six Middle
Eastern countries, and the use of follitropin alfa FbM
(rather than a formulation of urine-derived hFSH or
r-hFSH calibrated using the Steelman and Pohley bioassay).
Follitropin alfa FbM is assayed using a physicochemical
analytical method, which ensures a precise content per vial
and high batch-to-batch consistency [18].
Identification of factors predictive of response prior to
stimulation could also improve the efficacy and safety of
OI treatment protocols [16,22]. Such information would
allow FSH thresholds for successful ovulation to be bet-
ter estimated and individualized starting doses defined
[16,22]. In an analysis of data from two prospective, ran-
domized, Phase III, multicentre studies, low BMI, low
antral follicle count and high normal baseline FSH level
were associated with successful OI using a CLD r-hFSH
protocol [16]. Previous studies have also identified BMI
as a major determinant of successful ovulation, alongwith cycle history, baseline FSH level, insulin-like growth
factor I concentrations and previous history of response
to CC [14,23]. Obesity and insulin resistance have been
associated with adverse outcomes [14,23].
A potential limitation of the current study is the use of a
standard starting dose of r-hFSH regardless of the individ-
ual’s BMI (range 20–32 kg/m2). It is possible that failure
to tailor the initial dose of r-hFSH could have contributed
to the lack of difference in outcomes shown between the
two protocols.
Conclusions
This study provides valuable information on the efficacy
and safety of LD and CLD protocols used for OI in
women with WHO Group II anovulatory infertility in
the Middle East. The r-hFSH LD and CLD protocols re-
sulted in similar efficacy and safety outcomes; although
the CLD protocol may be more suitable in patients at
risk of multifollicular development.
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